Abstract
Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy modality that has shown remarkable response rates in refractory hematologic malignancies, including multiple myeloma (MM). Cytokine release syndrome (CRS) and neurotoxicity are well-described side effects of this therapy. CAR T-cell therapy recipients are also at increased risk for infections due to immune dysfunction, history of multiple lines of therapy, history of lymphodepleting chemotherapy prior to cell infusion, and prolonged B-cell aplasia. Progressive multifocal leukoencephalopathy (PML) is an opportunistic disease of the central nervous system caused by the reactivation of JC virus (JCV) in the setting of immunosuppression, which leads to increased morbidity and mortality. Here, we present a patient treated with ciltacabtagene autoleucel for refractory MM who presented with PML around 2 months after receiving CAR T-cell therapy. This case emphasizes the risks for the development of PML in immunocompromised patients potentially related to persistent B-cell aplasia, hypogammaglobulinemia, and prolonged immunosuppression and discusses treatment approaches. Treatments for PML are mostly focused on reconstituting immunity. However, no adequate treatment strategy for PML has yet been established and further research is needed.
References
Baldassari, L. E., Wattjes, M. P., Cortese, I. C. M., Gass, A., Metz, I., Yousry, T., Reich, D. S., & Richert, N. (2021). The neuroradiology of progressive multifocal leukoencephalopathy: A clinical trial perspective. Brain, 145(2), 426–440. https://doi.org/10.1093/brain/awab419
Barro, C., Benkert, P., Disanto, G., Tsagkas, C., Amann, M., Naegelin, Y., Leppert, D., Gobbi, C., Granziera, C., Yaldizli, Ö., Michalak, Z., Wuerfel, J., Kappos, L., Parmar, K., & Kuhle, J. (2018). Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain, 141(8), 2382–2391. https://doi.org/10.1093/brain/awy154
Belin, C., Devic, P., Ayrignac, X., Dos Santos, A., Paix, A., Sirven-Villaros, L., Simard, C., Lamure, S., Gastinne, T., Ursu, R., Berger, C., Platon, L., Tessoulin, B., Azoulay, E., Wallet, F., Thieblemont, C., Bachy, E., Cartron, G., Laplaud, D. A., & Carpentier, A. F. (2020). Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Scientific Reports, 10, Article 18997. https://doi.org/10.1038/s41598-020-76055-9
Berger, J. R., Neltner, J., Smith, C., & Cambi, F. (2014). Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica. Multiple Sclerosis and Related Disorders, 3(6), 728–731. https://doi.org/10.1016/j.msard.2014.08.004
Bernard-Valnet, R., Koralnik, I. J., & Du Pasquier, R. (2021). Advances in treatment of progressive multifocal leukoencephalopathy. Annals of Neurology, 90(6), 865–873. https://doi.org/10.1002/ana.26198
Berzero, G., Basso, S., Stoppini, L., Palermo, A., Pichiecchio, A., Paoletti, M., Lucev, F., Gerevini, S., Rossi, A., Vegezzi, E., Diamanti, L., Bini, P., Gastaldi, M., Delbue, S., Perotti, C., Seminari, E., Faraci, M., Luppi, M., Baldanti, F., Zecca, M., Marchioni, E., & Comoli, P. (2021). Adoptive transfer of JC virus-specific T lymphocytes for the treatment of progressive multifocal leukoencephalopathy. Annals of Neurology, 89(4), 769–779. https://doi.org/10.1002/ana.26020
Bhoj, V. G., Arhontoulis, D., Wertheim, G., Capobianchi, J., Callahan, C. A., Ellebrecht, C. T., Obstfeld, A. E., Lacey, S. F., Melenhorst, J. J., Nazimuddin, F., Hwang, W. T., Maude, S. L., Wasik, M. A., Bagg, A., Schuster, S., Feldman, M. D., Porter, D. L., Grupp, S. A., June, C. H., & Milone, M. C. (2016). Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood, 128(3), 360–370. https://doi.org/10.1182/blood-2016-01-694356
Bohra, C., Sokol, L., & Dalia, S. (2017). Progressive multifocal leukoencephalopathy and monoclonal antibodies: A review. Cancer Control, 24(4), 1073274817729901. https://doi.org/10.1177/1073274817729901
Bupha-Intr, O., Haeusler, G., Chee, L., Thursky, K., Slavin, M., & Teh, B. (2021). CAR-T cell therapy and infection: A review. Expert Review of Anti-infective Therapy, 19(6), 749–758. https://doi.org/10.1080/14787210.2021.1855143
Calderón-Ospina, C. A., & Nava-Mesa, M. O. (2019). B vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. CNS Neuroscience & Therapeutics, 26(1), 5–13. https://doi.org/10.1111/cns.13207
Chou, C. K., & Turtle, C. J. (2020). Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opinion on Biological Therapy, 20(6), 1–12. https://doi.org/10.1080/14712598.2020.1729735
Cortese, I., Muranski, P., Enose-Akahata, Y., Ha, S. K., Smith, B., Monaco, M., Ryschkewitsch, C., Major, E. O., Ohayon, J., Schindler, M. K., Beck, E., Reoma, L. B., Jacobson, S., Reich, D. S., & Nath, A. (2019). Pembrolizumab treatment for progressive multifocal leukoencephalopathy. New England Journal of Medicine, 380(17), 1597–1605. https://doi.org/10.1056/NEJMoa1815039
Cortese, I., Reich, D. S., & Nath, A. (2020). Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nature Reviews Neurology, 17(1), 37–51. https://doi.org/10.1038/s41582-020-00427-y
Cortese, I., Norato, G., Harrington, P. R., Usher, T., Mainardi, I., Martin-Blondel, G., Cinque, P., Major, E. O., & Sheikh, V. (2024). Biomarkers for progressive multifocal leukoencephalopathy: Emerging data for use of JC virus DNA copy number in clinical trials. The Lancet Neurology, 23(5), 534–544. https://doi.org/10.1016/S1474-4422(24)00099-1
Dunham, S. R., Schmidt, R., & Clifford, D. B. (2020). Treatment of progressive multifocal leukoencephalopathy using immune restoration. Neurotherapeutics, 17(3), 955–965. https://doi.org/10.1007/s13311-020-00848-z
Gauthier, J., & Turtle, C. J. (2020). Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Current Research in Translational Medicine, 66(2), 50–52. https://doi.org/10.1016/j.retram.2018.03.003
Goldman, A., Raschi, E., Chapman, J., Santomasso, B. D., Pasquini, M. C., Perales, M. A., & Shouval, R. (2023). Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells. Blood, 141(6), 673–677. https://doi.org/10.1182/blood.2022017386
Gong, Z., Umoru, G., Monge, J., Shah, N., Mohyuddin, G. R., Radhakrishnan, S. V., Chakraborty, R., Rasche, L., Schinke, C., D’Souza, A., & Mohan, M. (2024). Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: An FAERS database study. Blood Cancer Journal, 14(1), Article 36. https://doi.org/10.1038/s41408-024-01023-9
Jamilloux, Y., Kerever, S., Ferry, T., Broussolle, C., Honnorat, J., & Sève, P. (2016). Treatment of progressive multifocal leukoencephalopathy with mirtazapine. Clinical Drug Investigation, 36(10), 783–789. https://doi.org/10.1007/s40261-016-0433-8
Jung, S., Greiner, J., von Harsdorf, S., Popovic, P., Moll, R., Schittenhelm, J., Kandilaris, K., Daniel, V., Kunz, A., Schmitt, M., & Dreger, P. (2020). Fatal late-onset CAR T-cell mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma. Blood Advances, 5(19), 3789–3793. https://doi.org/10.1182/bloodadvances.2021004889
Koutsavlis, I. (2020). Progressive multifocal leukoencephalopathy in multiple myeloma: A literature review and lessons to learn. Annals of Hematology, 100(1), 1–10. https://doi.org/10.1007/s00277-020-04294-x
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Peggs, K., Pasquini, M., DiPersio, J. F., van den Brink, M. R. M., Komanduri, K. V., Grupp, S. A., & Neelapu, S. S. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625–638. https://doi.org/10.1016/j.bbmt.2018.12.758
Mian, A., Andrapalliyal, N., Weathers, A. L., Pohlman, B., & Hill, B. T. (2021). Late occurrence of progressive multifocal leukoencephalopathy after anti-CD19 chimeric antigen receptor T-cell therapy. European Journal of Haematology, 106(4), 584–588. https://doi.org/10.1111/ejh.13583
Möhn, N., Grote-Levi, L., Hopfner, F., Eiz-Vesper, B., Maecker-Kolhoff, B., Warnke, C., Sühs, K. W., Wattjes, M. P., Höglinger, G. U., & Skripuletz, T. (2022). Innovative therapeutic concepts of progressive multifocal leukoencephalopathy. Journal of Neurology, 269(5), 2403–2413. https://doi.org/10.1007/s00415-021-10952-5
Muftuoglu, M., Olson, A., Marin, D., Ahmed, S., Mulanovich, V., Tummala, S., Chi, T. L., Ferrajoli, A., Kaur, I., Li, L., Champlin, R., Shpall, E. J., & Rezvani, K. (2018). Allogeneic BK virus–specific T cells for progressive multifocal leukoencephalopathy. New England Journal of Medicine, 379(15), 1443–1451. https://doi.org/10.1056/NEJMoa1801540
Nelson, A. S., Yalamarthi, N., Yong, M. K., & Blyth, E. (2021). Beyond antivirals: Virus-specific T-cell immunotherapy for BK virus haemorrhagic cystitis and JC virus–progressive multifocal leukoencephalopathy. Current Opinion in Infectious Diseases, 34(6), 627–634. https://doi.org/10.1097/QCO.0000000000000794
Reveron-Thornton, R., Scott, B. J., Post, D., Caulfield, A. F., Werbaneth, K., Hovsepian, D. A., Spiegel, J., Miklos, D., Thomas, R. P., & Patel, C. B. (2022). Recurrent status epilepticus in the setting of chimeric antigen receptor (CAR)-T cell therapy. Neurohospitalist, 12(1), 74–79. https://doi.org/10.1177/19418744211000980
Siegler, E. L., & Kenderian, S. S. (2020). Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: Insights into mechanisms and novel therapies. Frontiers in Immunology, 11, Article 1973. https://doi.org/10.3389/fimmu.2020.01973
Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11(4), Article 69. https://doi.org/10.1038/s41408-021-00459-7
Stewart, A. G., & Henden, A. S. (2021). Infectious complications of CAR T-cell therapy: A clinical update. Therapeutic Advances in Infectious Disease, 8, 20499361211036773. https://doi.org/10.1177/20499361211036773
Tan, C. S., & Koralnik, I. J. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. The Lancet Neurology, 9(4), 425–437. https://doi.org/10.1016/S1474-4422(10)70040-5
Van Oekelen, O., Aleman, A., Upadhyaya, B., Schnakenberg, S., Madduri, D., Gavane, S., Teruya-Feldstein, J., Crary, J. F., Fowkes, M. E., Stacy, C. B., Kim-Schulze, S., Rahman, A., Laganà, A., Brody, J. D., Merad, M., Jagannath, S., & Parekh, S. (2021). Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine, 27(12), 2099–2103. https://doi.org/10.1038/s41591-021-01564-7
Wat, J., & Barmettler, S. (2022). Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: Characteristics, management, and future directions. Journal of Allergy and Clinical Immunology: In Practice, 10(2), 460–466. https://doi.org/10.1016/j.jaip.2021.10.037
Weber, T. (2008). Progressive multifocal leukoencephalopathy. Neurologic Clinics, 26(3), 833–854, xxi. https://doi.org/10.1016/j.ncl.2008.03.007
Yeung, J., van Hal, S., & Ho, P. J. (2019). Prolonged immunosuppression in relapsed, refractory multiple myeloma leading to cerebral toxoplasmosis and progressive multifocal leukoencephalopathy. Clinical Lymphoma, Myeloma & Leukemia, 19(12), e625–e628. https://doi.org/10.1016/j.clml.2019.09.617
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022). CAR-T cell therapy in hematological malignancies: Current opportunities and challenges. Frontiers in Immunology, 13, 927153. https://doi.org/10.3389/fimmu.2022.927153
